Conventional Therapeutic Antibodies Vs Nanobodies

Antibodies are routinely used in biochemistry, molecular biology and medical research but the greatest achievement has been their use as therapeutic agents.

Important advances have been made over the past decade to improve the engineering technologies, safety and efficacy of the first generation of therapeutic antibodies. These developments, along with a greater understanding of the immunomodulatory properties of antibodies, have paved the way for the next generation of new and improved antibody-based drugs for the treatment of human diseases. Here we will compare conventional therapeutic antibodies and novel nanobides.


The challenges faced by conventional therapeutic antibodies:

1. Long development cycle, high production cost, and high sales price (complex R & D, humanized and limited success rate);

2. Difficult to have mass production;

3. Unstable and easily degradable, high preservation cost; easy to be contaminated, high maintenance cost.


The advantages of Nanobody over conventional therapeutic antibodies in synthesis, operation, absorption and price:

1. Easy to obtain (immunity, B lymphocytes isolation, antibody library display technique);

2. Stable (internal folding contains multiple disulfide bonds and can be placed at room temperature);

3. High soluble;

4. High absorption;

5. The expression is easy (unlike conventional antibodies that must be expressed in mammalian cells, which is difficult, low yield, high cost; VHH can be highly expressed in prokaryotic cells);

6. Simple humanization process;

7. Easy to couple other molecules;


Creative Biomartis a company that offers quality nanobody products with its proprietary technology and experts’ devotion. For more information, please visit